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Abstract
Background: Aggregation of amyloid β into plaques in the brain is one of the earliest pathological events in
Alzheimer’s disease (AD). The exact pathophysiology leading to dementia is still uncertain, but the apolipoprotein E
(APOE) ε4 genotype plays a major role. We aimed to identify the molecular pathways associated with amyloid β
aggregation using cerebrospinal fluid (CSF) proteomics and to study the potential modifying effects of APOE ε4
genotype.
Methods: We tested 243 proteins and protein fragments in CSF comparing 193 subjects with AD across the
cognitive spectrum (65% APOE ε4 carriers, average age 75 ± 7 years) against 60 controls with normal CSF amyloid β,
normal cognition, and no APOE ε4 allele (average age 75 ± 6 years).
Results: One hundred twenty-nine proteins (53%) were associated with aggregated amyloid β. APOE ε4 carriers
with AD showed altered concentrations of proteins involved in the complement pathway and glycolysis when
cognition was normal and lower concentrations of proteins involved in synapse structure and function when
cognitive impairment was moderately severe. APOE ε4 non-carriers with AD showed lower expression of proteins
involved in synapse structure and function when cognition was normal and lower concentrations of proteins that
were associated with complement and other inflammatory processes when cognitive impairment was mild.
Repeating analyses for 114 proteins that were available in an independent EMIF-AD MBD dataset (n = 275) showed
that 80% of the proteins showed group differences in a similar direction, but overall, 28% effects reached statistical
significance (ranging between 6 and 87% depending on the disease stage and genotype), suggesting variable
reproducibility.
Conclusions: These results imply that AD pathophysiology depends on APOE genotype and that treatment for AD
may need to be tailored according to APOE genotype and severity of the cognitive impairment.
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Background
Amyloid β aggregation in the brain is one of the earliest
pathological events in Alzheimer’s disease (AD) and is
thought to start decades before the manifestation of de-
mentia [1–3]. The presence of an apolipoprotein E
(APOE) ε4 allele, the major genetic risk factor for AD
[4], lowers the age of onset through an as of yet un-
known mechanism. In general, it is largely unclear which
biological processes eventually lead to cognitive decline
once amyloid β has aggregated, as well as whether such
processes are influenced by the presence of the APOE ε4
allele. A better understanding of the biological processes
disrupted in AD subjects is crucial for the development
of precision medicine. The apoE4 protein isoform has
been associated with impaired amyloid clearance and
transport, synaptogenesis, and glucose and cholesterol
metabolism in the brain [5, 6]. However, about 25–40%
of patients with AD dementia lack the APOE ε4 allele
[7], and for these individuals, the pathophysiological
mechanisms involved in AD are less clear [8]. Unbiased
proteomic analysis in cerebrospinal fluid (CSF) allows
studying multiple molecular processes at the same time
in patients, and it can be hypothesized that distinct pat-
terns of protein concentrations exist in the CSF that are
associated with aggregated amyloid. The first CSF prote-
omic studies have identified novel markers associated
with AD-type dementia when comparing patients with
cognitively normal controls [9–11]. Yet, not all subjects
with a clinical diagnosis of AD-type dementia have ag-
gregated amyloid, and on average, 30% of cognitively
normal subjects are already in the preclinical stage of
AD [3, 12, 13]. Consequently, it remains uncertain which
of the previously reported markers are specific for AD
pathology, i.e., aggregated amyloid. Furthermore, protein
levels in CSF may depend on APOE ε4 genotype, which
has been reported for beta secretase-1 [BACE1] [14] and
chitinase-3-like protein 1 [YKL40] [15], both proteins as-
sociated with AD-type dementia, and so, it is plausible
that APOE ε4 genotype may influence other protein
markers in the CSF as well.
In this study, we used a CSF proteomic approach to
test the hypothesis that protein signatures can be de-
tected that show APOE ε4 genotype-dependent associa-
tions with AD across the cognitive spectrum.
Methods
Participants
We downloaded ADNI data in August 2017 from the
ADNI database (all data is available at adni.loni.usc.edu),
including participants from over 50 sites across the USA
and Canada (www.adni-info.org). As such, the investiga-
tors within the ADNI contributed to the design and im-
plementation of ADNI and/or provided data but did not
participate in the analysis or writing of this report.
Further details about ADNI are given in the “Acknowl-
edgments” section. Study protocols were approved by
the institutional review boards of all participating ADNI
centers (a complete list of ADNI sites is available at
http://adni.loni.usc.edu/about/centers-cores/study-sites/
), and written informed consent was obtained from all
participants or authorized representatives. All analyses
were performed on de-identified ADNI data, and
methods were carried out in accordance with the ap-
proved guidelines.
For the present study, we included individuals who
had baseline CSF data available for amyloid β 1–42 and
proteomics (see the next section). Aggregated amyloid in
CSF was defined as having CSF amyloid β 1–42 levels
below 192 pg/ml [16]. APOE genotype was assessed with
two SNPs (rs429358, rs7412) that define the epsilon 2, 3,
and 4 alleles, using DNA extracted by Cogenics from a
3-ml aliquot of EDTA blood. Subjects were classified ac-
cording to amyloid status (normal/abnormal), APOE ε4
genotype (carrier/non-carrier), and cognitive stage as
measured with the MMSE [17] (normal cognition:
MMSE > 27; mild impairment: MMSE scores between
27 and 24; moderate impairment: MMSE < 24).
CSF protein analysis
CSF samples were collected with a lumbar puncture, and
samples were stored at the ADNI Core Laboratory at the
University of Pennsylvania Medical Center on dry ice
until further analysis. In total, 313 proteins and protein
fragments were measured: 12 with ELISA, 159 with pro-
teomics RBM, and 142 with proteomics multiple reac-
tion monitoring (MRM) targeted mass spectroscopy (see
supplementary table 1 for an overview of all included
proteins). Information on protein assessment and quality
control is described at http://adni.loni.usc.edu/data-sam-
ples/biospecimen-data/. For MRM, we used the finalized
“Normalized Intensity” data [9], which was the result of
a two-step normalization procedure of the raw peak area
data to remove variability between samples processed on
different days introduced by the depletion method: First,
process-related bias was removed by correcting for
trends when observed, by computing the predicted aver-
age log-intensity values from smoothing spline function
to the CSF sample averages. For each sample at a given
transition, the predicted value was subtracted from the
sample average log-intensity. Second, using two regres-
sion models to model the daily sample average and the
global sample average, the log-intensity values of the
CSF samples after step 1 normalized were further
normalized to account for the depletion day of the sam-
ples. (please see for a detailed explanation of the
normalization procedure the “Biomarkers Consortium
CSF ProteomicsMRM data set” in the “Data Primer”
document at adni.loni.ucla.edu). All CSF protein levels
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were Z-transformed to the control group (normal amyl-
oid, APOE ε4 non-carrier, MMSE > 27), such that nega-
tive values indicate lower and positive values indicate
higher levels compared to the normal state. If peptides
from the same protein showed a moderate to strong cor-
relation (r > .6), we combined peptides into a composite
measure by averaging their Z scores. This resulted in
243 protein measures tested. A subset of 114 proteins
tested in the present study was also measured with tan-
dem mass tag spectrometry in the multi-center EMIF-
AD Multimodal Biomarker Discovery (MBD) study [18]
which we used for replication analyses.
Statistical analysis
t test, χ2, and Kruskal-Wallis tests were used to com-
pare the subject characteristics between the AD and
control groups. We compared the protein levels be-
tween subjects with AD (defined as having aggregated
amyloid) and the control group, stratified for APOE
ε4 genotype and cognitive stage with ANCOVAs that
included age and gender as potential confounders. All
statistical analyses were performed using R, version
3.2.3.
Pathway enrichment analyses
We used the online database STRING [19] to identify
enriched biological processes (based on KEGG pathways
and GO biological processes) for each protein that
showed significant differences with the control group. In
addition, we used this database to test for pathway en-
richment entering all proteins associated with a particu-
lar group at the same time.
Results
Sample characteristics by APOE ε4 genotype
In total, 253 individuals from the Alzheimer’s Disease
Neuroimaging Initiative-1 (ADNI-1) had available base-
line proteomic CSF data. Compared to the control
group, APOE ε4 carriers and non-carriers with aggre-
gated amyloid β had similar average age, level of educa-
tion, and gender distributions (Table 1).
Figure 1 shows that proteins associated with aggre-
gated amyloid formed distinct clusters depending on the
APOE genotype and cognitive stage. In total, 129 (53%)
proteins and protein fragments were associated with ag-
gregated amyloid, with 27 (21%) proteins showing higher
levels and the majority of proteins (102, 79%) showing
lower levels in AD compared to controls. The large
Table 1 Sample description



























60 (23%) 24 (9%) 34 (13%) 9 (3%) 8 (3%) 40 (15%) 63 (24%) 23 (27%)
E2/E3 15 (25%) 3 (12.5%) 6 (18%) 0 0 0 0 0
E3/E3 45 (75%) 21 (87.5%) 28 (82%) 9 (100%) 0 0 0 0
E2/E4 0 0 0 0 0 1 (2.5%) 2 (3%) 1 (4%)
E3/E4 0 0 0 0 8 (100%) 34 (85%) 41 (68%) 13 (57%)
E4/E4 0 0 0 0 0 5 (12.5%) 20 (33%) 9 (39%)
Age 75.30 (6.44) 76.70 (4.90) 75.37 (8.10) 78.82 (5.55) 72.1 (6.43) 74.97 (6.16) 74.53 (6.88) 73.32 (8.70)
Female, N (%) 29 (48%) 10 (42%) 13 (38%) 4 (44%) 4 (50%) 12 (30%) 30 (48%) 8 (35%)
Education
years
16.00 (2.76) 16.08 (3.32) 15.62 (3.29) 16.22 (3.23) 15.50 (2.00) 16.02 (3.22) 15.25 (2.83) 15.30 (2.67)



































6.18 (2.18) 5.98 (3.26) 5.84 (2.68) 5.61 (4.44) 10.07 (5.80)c 11.92 (1.24)*** 11.89 (1.43)*** 11.63 (1.17)***
Values are mean (SD). All comparisons are made against the control group (APOE ε4 non-carriers with normal amyloid and MMSE > 27). APOE ε4 isoform is the
protein fragment that is specifically encoded by the ε4 allele, average log-intensity value are provided (all non-carriers have values below the level of detection,
Spellman et al., 2015)
*p < .05, **p < .01, ***p < .001
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majority (90%) of proteins associated with aggregated
amyloid showed expression differences with controls
that depended on the cognitive stage. Tau, another
major pathological hallmark for AD, was the only pro-
tein that showed higher levels in all AD subjects across
the cognitive spectrum, with higher concentrations for
Fig. 1 Left, heatmap of proteins associated with amyloid pathology. Columns indicate APOE ε4 carriers and non-carriers with AD according to
the severity of their cognitive impairment (MMSE > 27, 27–24, or < 24). Color scale indicates the Z value of proteins showing a significant
difference (p < .05) compared with the control group (APOE ε4 non-carriers with normal amyloid and MMSE > 27). Proteins are expressed as Z-
scores using the control group as a reference and plotted when showing a significant difference (p < .05). Light blue indicates non-significance
(p > .05). Right, the percentage of proteins associated with one of the 11 biological process categories. Percentages were calculated with disease
stage-specific total numbers of proteins associated with abnormal amyloid, and the number of proteins is given below each disease stage. Please
see supplementary table 3 for a detailed description of biological processes enriched
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more severe impairment, regardless of APOE ε4 status.
We further observed two patterns of protein expression
levels: (1) 83 of the 129 proteins (64%) had altered levels
either in ε4 carriers or non-carriers; (2) 46 of the 129
proteins (36%) had altered levels in both APOE ε4 car-
riers and non-carriers, but in different cognitive stages.
APOE ε4 genotype associations of proteins with
aggregated amyloid β
Compared to controls, APOE ε4 carriers with normal
cognition showed higher levels of nicastrin [NCSTN],
which is part of the gamma secretase complex, and of a
group of proteins that were associated with glycolysis
(Fig. 1, first column; supplementary table 1). Carriers
further showed higher levels of markers known to in-
crease with neuronal injury (neurogranin [NRGN]; fatty
acid-binding protein, heart [FABP3]; visinin-like protein-
1[VILIP1]; YKL40), growth factors fibroblast growth
factor-4 [FGF4], and hepatocyte growth factor [HGF]
[20]. These proteins were also higher in subjects with
mild and moderate cognitive impairment. Furthermore,
a large group of proteins had lower levels in AD, includ-
ing immune system-related complement factors (C2, C3,
C5, C6, factor-B [CFB], factor-H [CFH]) and factors that
interact with the complement system (plasminogen
[PLG], prothrombin [F2], serum amyloid P component
[APCS], and C-reactive protein [CRP]). Subjects with
moderate cognitive impairment showed lower levels of
proteins that were mostly associated with cell adhesion-
related processes (Fig. 1, fifth column), including
markers functionally associated with “transsynaptic sig-
naling”(e.g., cadherin-13 [CDH13], neogenin [NEO1],
neural cell adhesion molecule-1 [NCAM1], neuronal cell
adhesion molecule [NRCAM]), “peptide neurotrophin
signaling” (chromogranin-A [CHGA], proenkephalin-B
[PDYN], secretogranin-2 [SCG2], proSAAS [PCSK1]),
and “GPCR signaling”(glutamate receptor-4 [GRM4],
latrophilin-1 [ADGRL1]) [21]. The top pathways
enriched in KEGG for proteins associated with aggre-
gated amyloid were “complement and coagulation
cascades” for subjects with normal cognition; no
enrichment was observed in mild impairment, and for
moderate cognitive impairment “cell adhesion mole-
cules” (Table 2).
APOE ε4 non-carrier associations of proteins with
aggregated amyloid β
APOE ε4 non-carriers with aggregated amyloid showed
a different proteomic profile than APOE ε4 carriers, in
the type of proteins expressed and/or the cognitive stage
of expression. Non-carriers with normal cognition
showed lower levels of a large group of proteins associ-
ated with cell adhesion processes compared to the
control group (Fig. 1; supplementary table 2). A subset
of these proteins included synaptic markers contactin-1
[CNTN1], neurexin-1 [NRXN1] and neurexin-2
[NRXN2] that were associated with “transsynaptic sig-
naling” [21], and the neuronal pentraxin receptor
[NPTXR]. In this stage, only tau showed higher levels.
APOE ε4 non-carriers with mild impairment showed
lower levels of complement-related proteins, which over-
lapped with the complement proteins that showed lower
levels in APOE ε4 carriers with normal cognition. Fur-
ther, alterations observed in non-carriers with mild im-
pairment were higher levels of a wide range of neuronal
injury markers (NRGN, FAPB3, VILIP1). APOE ε4 non-
carriers with moderate cognitive impairment also had
higher levels of glial fibrillary acidic protein [GFAP],
neurofilament light [NFL], resistin [RETN], and macro-
phage migration inhibitory factor [MIF]. These proteins
did not show a clear association with a shared biological
pathway (Fig. 1, sixth column), but might be related to
inflammatory responses. In addition, sortilin [SORT1]
levels were higher in these subjects. SORT1 has several
functions and is involved in APP processing [22]. No
proteins showed lower levels in this stage, but it should
be noted that this group had a small sample size, which
may have limited statistical power. The top pathways
enriched in KEGG for proteins associated with aggre-
gated amyloid in APOE ε4 non-carriers were “cell adhe-
sion molecules” for subjects with normal cognition and
Table 2 Summary of pathways enriched in KEGG of proteins associated with aggregated amyloid according to APOE ε4 genotype
Cognitive
stage
APOE ε4 carriers APOE ε4 non-carriers




























CADM3’, CNTN1, CNTNAP2, NCAM1, NEGR1,




Please note that APOE and APP were excluded from enrichment analyses. Bold font indicates concordant difference compared to controls observed in EMIF-AD
MBD; apostrophe (’) indicates not available in independent cohort
n.a not applicable, MMSE Mini-Mental State Examination, FDR false discovery rate
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“complement and coagulation cascades” for subjects
with mild impairment (Table 2).
APOE ε4 effect on amyloid processing in asymptomatic
subjects with normal amyloid β
We further explored whether protein differences could
be observed in APOE ε4 carriers with normal amyloid β
and cognition, as these subjects are at increased genetic
risk of developing amyloid pathology [4], and so, for
these subjects, proteomic alterations may indicate very
early pathological changes associated with AD. Injury
markers were normal in these subjects. Compared to the
control group, ten proteins (APOE ε4 fragment, tau
[MAPT], BACE1, β-nerve growth factor [NGF], macro-
phage inflammatory protein-1β [CCL4], osteopontin
[SPP1], AXL receptor tyrosine kinase [AXL], heparin-
binding EGF-like growth factor [HBGF], carbonic
anhydrase-1 [CA1], interferon gamma-induced protein-
10 [CXCL10]) showed altered levels (Fig. 2). The top
KEGG pathway enriched was the Toll-like receptor
signaling pathway (pFDR = 0.00033; including SPP1,
CXCL10, and CCL4).
Replication in the independent EMIF-AD MBD cohort
Finally, we performed replication analyses in the inde-
pendent EMIF-AD MBD cohort by comparing the con-
cordance of observed group differences compared to
controls. Overall, individuals in EMIF-AD MBD were
younger than in ADNI and showed lower levels of edu-
cation (supplementary table 4). APOE ε4 carriers with
mild impairment were more often female in EMIF-AD
MBD (54%) than in ADNI (30%). Of the 136 proteins/
fragments that showed an association with amyloid
aggregation in the carrier or non-carrier groups, 114
were also measured in the EMIF-AD MBD, and across
all contrasts, 80% showed concordant group differences
compared to controls. Within in the APOE ε4 carriers,
individuals with mild and moderate cognitive impair-
ment showed high concordances in group differences of
respectively 93% of 13 overlapping proteins and 95% of
63 overlapping proteins (Fig. 3; supplementary table 1),
and individuals with normal cognition showed moderate
concordance of 58% of 40 overlapping proteins. APOE
ε4 carriers with normal cognition and normal amyloid
showed concordance of 100% of 4 overlapping proteins.
In the APOE ε4 non-carriers, individuals with mild im-
pairment showed a low level of concordance of 28% of
36 overlapping proteins, and individuals with normal
cognition and moderate cognitive impairment showed
high concordance (respectively 87% of 15 overlapping




In this study, both APOE ε4 carriers and non-carriers
with abnormal CSF amyloid β 1–42 levels showed alter-
ations of large groups of proteins involved in neuronal
injury, complement and inflammatory processes, and cell
adhesion processes, but in a different temporal ordering.
APOE ε4 carriers showed altered protein levels of com-
plement related proteins in the normal cognition stage,
while lower levels of proteins associated with cell adhe-
sion and synaptic signaling were found in cognitive im-
pairment stages. Non-carriers with aggregated amyloid
showed a reversed temporal ordering of these processes
Fig. 2 Proteins associated with APOE ε4 carrier status in subjects with normal amyloid. Z-scores are plotted for proteins that were different
between subjects with APOE ε4 (in brown) and normal amyloid and normal cognition (MMSE > 27) compared to the control group (i.e., in blue).
All values are standardized according to the control group (i.e., APOE ε4 non-carriers with normal amyloid and MMSE > 27)
Konijnenberg et al. Alzheimer's Research & Therapy           (2020) 12:65 Page 6 of 11
with proteins involved in cell adhesion processes show-
ing altered levels in cognitively normal subjects, which
was followed by alterations in complement-related pro-
teins in cognitive impairment stages. These results sug-
gest that subjects with AD may require specific
treatment tailored to their APOE genotype and degree
of cognitive impairment.
CSF proteome signatures associated with APOE ε4
APOE ε4 carriers with normal cognition showed lower
levels of complement-related proteins C2, C3, C5, C6,
CFB, CFH, PLG, F2, APCS, and CRP. The complement
system is a major part of the innate immune system, and
its classical activation pathway can be directly triggered
by amyloid aggregates [23, 24]. Previous studies investi-
gating complement-related protein concentrations in
CSF have, however, reported divergent results with
higher concentrations in AD-type dementia patients
[25–27] and also lower concentrations in AD-type de-
mentia patients [28] and in subjects with mild cognitive
impairment who showed cognitive decline at follow-up
[27]. Our results suggest that levels may be altered in
different cognitive stages according to APOE genotype,
with ε4 carriers showing more extensive complement in-
volvement in the cognitively normal stage, whereas non-
carriers showed alterations in the mild impairment stage.
Possibly, this observation reflects that the apoE4 protein
enhances complement activation in the presence of ag-
gregated amyloid β [29]. However, only a subset of these
proteins (KNG1, CFH, C2) showed similar differences in
the replication cohort, and these were less pronounced.
The replication cohort further showed contrary group
differences compared to ADNI for C6, CFB, F2, and
PLG in both APOE carriers with normal cognition and
in APOE non-carriers with mild impairment. This sug-
gests that the different proteomic techniques may differ
in sensitivity to measure these proteins accurately, and
future research should further investigate this issue by
comparing both techniques within the same cohort. At
this point, we can only speculate as to how reduced
levels of complement proteins in CSF can be interpreted.
Lower protein concentrations may reflect binding of
complement proteins to pathogen surfaces, possibly to
tag these for phagocytosis [23], and the presence of com-
plement proteins in amyloid plaques seems to support
this explanation [23, 24, 30]. Alternatively, lower levels
of complement proteins could point towards decreased
production, which seems to be in line with the observa-
tion that regulators of complement activation like CFH
also showed lower levels in these subjects. Furthermore,
APOE e4 carriers MMSE>27 versus controls APOE e4 carriers MMSE 27-24 versus controls
APOE e4 non-carriers MMSE>27 versus controls APOE e4 non-carriers MMSE 27-24 versus controls
APOE e4 carriers MMSE <24 versus controls
APOE e4 non-carriers MMSE <24 versus controls
a)
b)





































































































































































































































Fig. 3 Effect size plots for 114 proteins measured in both ADNI and EMIF-AD MBD studies. a Effects for protein differences of individuals with
abnormal amyloid carrying and ≥ 1 APOE ε4 allele against controls (i.e., APOE ε4 non-carriers with normal amyloid and MMSE > 27) according to
the severity of their cognitive impairment (MMSE > 27, 27–24, or < 24), and at the far left for APOE ε4 carriers with normal amyloid and MMSE >
27. In blue, effect sizes and 95%CI for ADNI; in orange, for EMIF-AD MBD. b Effects for protein differences of individuals with abnormal amyloid
carrying without an APOE ε4 allele against controls (i.e., APOE ε4 non-carriers with normal amyloid and MMSE > 27) according to the severity of
their cognitive impairment (MMSE > 27, 27–24, or < 24). In blue, effect sizes and 95%CI for ADNI; in orange, for EMIF-AD MBD
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carriers in the moderate cognitive impairment stage
showed lower levels than controls of complement C1q
subcomponent subunit-B [C1QB] and CD59, which was
also observed in the replication cohort. C1q can directly
bind to amyloid β fibrils, which can lead to activation of
C1 as well as C3 [24, 31]. Whereas C3 is associated with
several pathways of the complement system, C1QB is
specific for classical complement activation [23, 24]. The
involvement of different complement proteins according
to cognitive stage suggests that triggers of the comple-
ment system might exist that depend on the level of
neuronal injury and/or the degree of amyloid fibril for-
mation. Future research should further study how com-
plement levels change longitudinally during the
development of AD, and how these processes depend on
APOE genotype.
Alterations of complement protein concentrations
were accompanied by a range of inflammatory markers
in APOE ε4 carriers, some of these showing altered
levels in carriers who had still normal amyloid β levels,
suggesting that inflammation processes may play a role
in the development in AD before amyloid aggregation
becomes manifest in CSF. Some of these markers have
been associated with microglia dysfunction or response
associated with neurodegeneration (AXL, SPP1, FABP3)
[32, 33] and reactive astrocytes (CCL4, S100 calcium
binding protein B [S100B], YKL40, GFAP) [34]. In
APOE ε4 non-carriers, most of these protein levels were
similar to controls, except for inflammation markers
SPP1, FABP3 (also in the replication cohort), and GFAP
that were higher in more severe stages of cognitive im-
pairment. Together, these results support the notion that
inflammation plays an important role in AD [35], and
we further show that the timing of involved inflamma-
tion processes seem to depend on APOE genotype. It is
conceivable that these differences reflect apoE isoform-
specific interactions with astrocyte and microglia func-
tioning [32, 33, 36, 37].
APOE ε4 carriers with normal amyloid β showed
higher levels of BACE1, which is the secretase that initi-
ates amyloidogenic processing of APP [38]. This suggests
that increased APP processing might be a pre-amyloid
event [39]. Tau levels were also already increased, al-
though lower than in carriers with normal cognition
who showed aggregated amyloid. Cognitively normal
APOE ε4 carriers with aggregated amyloid further
showed higher levels of proteins associated with glycoly-
sis, which was also observed in the replication cohort.
High levels of proteins involved in glycolysis have previ-
ously been reported in brain pathology studies in early
stage AD [40]. APOE ε4 has been associated to dysfunc-
tion of mitochondria [41], and so increased levels of gly-
colysis may indicate compensation for mitochondrial
dysfunction [41–44]. In the mild impairment stage,
APOE ε4 carriers showed lower levels of a small group
of cell adhesion molecules, and substantially more cell
adhesion proteins showed lower levels in the moderate
impairment stage, among which proteins associated with
synapse development (NPTXR, NRCAM, NEO1,
NCAM1, CDH13), which was also observed in the repli-
cation cohort [21]. In addition, proteins that showed
lower concentrations than controls were associated with
presynaptic dense core vesicles (CHGA, secretogranin-3
[SGC3], voltage-dependent calcium channel subunit
alpha-2 delta-1 [CACNA2D1], PDYN, CDH13, SPARC-
like protein 1[SPARCL1], alpha-1 antitrypsin [SER-
PINA1]) [45]. These proteins are associated with peptide
neurotrophin signaling. Since synapse loss correlates
well with cognitive decline [46], and in more severe cog-
nitive impairment stages these proteins showed lower
levels, also in the replication cohort, this might indicate
impaired synaptic functioning. However, APOE ε4 non-
carriers showed normal levels of the majority of these
proteins despite the same stage of cognitive impairment
and similar levels of neuronal injury markers.
CSF proteome signatures associated with aggregated
amyloid β in APOE ε4 non-carriers
Non-carriers with aggregated amyloid and normal cogni-
tion showed lower levels of presynaptic proteins (NRX1
and NRX2), proteins involved intracellular trafficking
(vacuolar protein sorting 10 [VPS10], domain-containing
receptor SorCS1 [SORCS1]), and neuronal pentraxins
[47], suggesting alterations in the presynaptic cell struc-
ture may be an early event in AD for subjects lacking
the ε4 allele. These differences with controls were also
observed in the replication cohort, albeit less pro-
nounced. In particular, SORCS1 stands out in this
group, as this gene has been associated with an increased
risk for AD [48], and this protein plays a key role in
intracellular sorting and trafficking of proteins, including
APP, neuronal pentraxins, and NRX1 and NRX2 [48–
50]. This leads us to propose that the lower levels we
observed presently in ε4 non-carriers with still normal
cognition might reflect disruption of these cellular trans-
port mechanisms and subsequent failure of intracellular
processes such as protein recycling, exocytosis, or autop-
hagocytosis. Levels of the synaptic proteins were low in
the mild impairment stage, and in that stage, additional
proteins associated with cell adhesion processes, like,
e.g., cell adhesion molecule-3 [CADM3] also showed
lower levels. The replication cohort showed, however,
higher levels for those proteins. It is unclear whether this
reflects differences in disease stage, or age, as the repli-
cation cohort was younger. Differences in the results be-
tween the cohorts may also reflect the differences
between proteomic techniques. More research is needed
that use the same proteomics technique in larger
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samples of non-carriers with mild impairment to further
investigate this issue. Another finding was that we ob-
served higher NFL levels in non-carriers in both cohorts.
Higher levels of CSF NFL indicate axonal injury, and
such higher levels have been associated with neurode-
generative processes in several neurological disorders [51].
Strengths and limitations
A potential limitation of this study is that the interpret-
ation of higher and lower levels of proteins measured in
CSF in terms of activated biological processes is not al-
ways straightforward. However, interpretations for some
proteins, such as amyloid β and tau, have been well
established through associations with histopathological
measurements in post-mortem research [52] and/or with
PET imaging [53]. Still, 80% of the associations for pro-
teins that were also measured in an independent repli-
cation cohort showed group differences in a similar
direction, but this depended on the specific group stud-
ied, and small sample sizes of these subgroups (particu-
larly so for the non-carriers with MMSE < 24 and the
carriers with normal amyloid and MMSE > 27) may have
limited the statistical power to observe significant re-
sults. Therefore, more studies are needed to replicate
these findings in larger samples. Nevertheless, our re-
sults may be useful to select proteins for further detailed
studies, as these seem to be involved in AD pathology
in vivo. Another point of note is that proteins measured
in ADNI were specifically selected based on their associ-
ation with biological processes relevant for AD. As such,
pathway enrichment analyses should not be seen as dis-
covery of new processes involved, but rather were meant
to aid interpretation of the results. The enriched pro-
cesses associated with abnormal amyloid where specific
for clinical stage and genotype, and it is unlikely that en-
richment of these processes simply reflect the processes
associated with the proteins that were selected in this
study, because the background set of proteins was the
same each analysis. Untargeted proteomic techniques
should be used in order to discover involvement of po-
tential other pathways that may be associated with AD
in an APOE dependent way. Another point of note is
that the control group contained more E2 carriers than
the APOE ε4 carriers, and consequently, differences
between these groups may also contain E2-specific
effects, which may not directly reflect amyloid abnormal-
ity. Furthermore, APOE ε4 carriers with MMSE > 27
were less often ε4 homozygous than carriers with MMSE
< 27 and abnormal amyloid, and such dose effects may
have contributed to the different sets of proteins
observed to be related with abnormal amyloid between
these stages. Future studies should aim to collect larger
samples of individuals in order to determine dosage
effects on the CSF proteome.
Furthermore, we have operationalized disease severity
in our sample based on the MMSE, which is a screening
tool. An alternative approach would have been
categorization based on syndrome diagnosis, but a draw-
back of that approach is that individuals with normal
cognition, MCI, and dementia can have the same
MMSE. At this point, no tools exist that accurately de-
lineates disease severity in a non-demented population,
and future research should focus on developing tools
that are sensitive to cognitive impairment in pre-
dementia stages of AD. Another potential limitation is
that we labeled proteins based on the top pathways
found, and although this simplifies the interpretation of
the results, this approach does not take into account the
notion that proteins could be involved in multiple bio-
logical processes. In addition, in the present study, we
defined AD based on abnormal CSF amyloid levels, be-
cause (as of yet) the majority (97%) of subjects did not
have pathological data available, which can be seen as a
limitation of this study. Still, it has been shown previ-
ously that amyloid biomarker values correlate with histo-
pathological measures for amyloid plaques [52]. Using
biomarkers to define AD can also be regarded to be a
strong aspect of our study. This way, we avoided poten-
tial biases in our results that may arise when defining
groups based only on clinical characteristics, as clinical
features do not always accurately reflect the underlying
pathology. Finally, although our results suggest that sev-
eral processes associated with aggregated amyloid might
be transient, further longitudinal CSF proteomic studies
are required to investigate these dynamics in more
detail.
Conclusions
In conclusion, we found CSF proteomic signatures that
were associated with aggregated amyloid β and were
dependent on APOE ε4 genotype and cognitive stage.
An implication of our results is that AD subjects may re-
quire treatments tailored to APOE genotype and that
clinical trials may need to consider APOE ε4 dependent
endpoints in CSF.
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